Skip to content
Regulatory

FDA Peptide Timeline 2026

The 2026 timeline of FDA action on therapeutic peptides — the April 15 reclassification, the July Pharmacy Compounding Advisory Committee meeting, and the post-PCAC implementation arc.

April 15, 2026 — Reclassification

The FDA published a Federal Register notice removing twelve therapeutic peptides — BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, Epitalon, GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF — from Category 2 of the 503A bulk drug substances evaluation framework. The action moves these compounds to an interim evaluation tier pending final 503A Bulks List placement.

Practical effect: Licensed 503A compounding pharmacies may now legally prepare these peptides under valid patient-specific prescriptions. The previous Category 2 status had operated as a de facto freeze on at-scale compounding.

April 15 to July 23 — Interim window

The 90-day window between reclassification and the PCAC decision is when the supply chain repositions. Compounding pharmacies are credentialing additional state non-resident registrations, hiring peptide-specific pharmacist expertise, and standing up quality protocols ahead of the post-PCAC volume surge. Telehealth brands with GLP-1 prescribing infrastructure are preparing peptide-category expansions for August/September launch.

July 23–24, 2026 — PCAC meeting

The Pharmacy Compounding Advisory Committee will meet to recommend final 503A Bulks List placement for each of the twelve reclassified peptides. PCAC is a 13-member advisory panel; its recommendations are advisory but historically adopted by the FDA with high fidelity.

Three outcomes are possible per peptide: full approval, approval with restrictions, or referral for further study. Full breakdown of likely outcomes →

August – September 2026 — Implementation

Following the PCAC recommendation, the FDA finalizes Bulks List placement. Compounding pharmacies shift from interim-tier to final-list workflows. Telehealth brands launch peptide formularies. Volume surge begins. Counterfeit pressure on the gray market intensifies.

Q4 2026 — Mature market

Post-PCAC retail pricing settles. Direct-to-consumer telehealth pricing emerges in the $60–90/vial range; PCAB-accredited compounders settle in the $100–200/vial range. State-by-state friction points become more visible as regulatory variance is tested by national-scale ordering volume.

Sources we monitor